Bronchial asthma is pushed by group 2 innate lymphoid cells, antigen-specific CD4+ T helper sort 2 cells and their cytokines corresponding to interleukin (IL)-4, IL-5, IL-13. IL-37 is decreased in bronchial asthma and negatively associated to Th2 cytokines and different pro-inflammatory cytokines. Our examine confirmed that IL-37 degree in asthmatic peripheral blood mononuclear cells was decrease than in wholesome.

Additional, IL-37 was negatively correlated with exhaled nitric oxide, bronchial asthma management take a look at rating, atopy and rhinitis historical past in asthmatics. Then an OVA-induced bronchial asthma mice mannequin handled with rhIL-37 was established.

An antibody array was employed to uncover altered cytokines induced by IL-37 in mice lung tissue. 20 proteins differentially expressed after rhIL-37 therapy and 5 of them have been validated in asthmatic peripheral blood mononuclear cells. According to cytokine antibody array, CCL3, CCL4, CCL5 decreased after IL-37 administration. Whereas CXCL9 and CXCL13 have been no change. We concluded that IL-37 scale back asthmatic signs by inhibit pro-inflammatory cytokine corresponding to CCL3, CCL4, CCL5.

T cell engineering methods provide cures to sufferers and have entered scientific observe with chimeric antibody-based receptors; αβT cell receptor (αβTCR)-based methods are, nonetheless, lagging behind. To permit a extra speedy and profitable translation to profitable ideas additionally utilizing αβTCRs for engineering, incorporating a technique for the purification of genetically modified T cells, in addition to engineered T cell deletion after switch into sufferers, might be useful.

This might enable elevated efficacy, lowered potential unwanted side effects, and improved security of newly to-be-tested lead constructions. By characterizing the antigen-binding interface of a great manufacturing course of (GMP)-grade anti-αβTCR antibody, normally used for depletion of αβT cells from stem cell transplantation merchandise, we developed a method that permits for the purification of untouched αβTCR-engineered immune cells by altering 2 amino acids solely within the TCRβ chain fixed area of launched TCR chains.

Alternatively, we engineered an antibody that targets an prolonged mutated interface of 9 amino acids within the TCRβ chain fixed area and gives the chance to additional develop depletion methods of engineered immune cells.

Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis manifests with precipitous cognitive decline, irregular actions, and extreme seizures that may be difficult to manage with typical anti-seizure drugs. We beforehand demonstrated that intracerebroventricular (i.c.v.) administration of cerebrospinal fluid from affected sufferers, or purified NMDA receptor antibodies from encephalitis sufferers to mice precipitated seizures, thereby confirming that antibodies are straight pathogenic for seizures.

Though completely different repertoires of anti-NMDA receptor antibodies might contribute to the distinct scientific manifestations in encephalitis sufferers, the position of particular antibodies within the expression of seizure, motor, and cognitive phenotypes stays unclear. Utilizing three completely different patient-derived monoclonal antibodies with distinct epitopes throughout the N-terminal area (NTD) of the NMDA receptor, we characterised the seizure burden, motor exercise and anxiety-related conduct in mice.

We discovered that steady administration of 5F5, 2G6 or 3C11 antibodies for two weeks precipitated seizures, as measured with steady EEG utilizing cortical screw electrodes. The seizure burden was comparable in all three antibody-treated teams. The seizures have been accompanied by elevated hippocampal C-C chemokine ligand 2 (CCL2) mRNA expression Three days after antibody infusion had stopped.

Anti-PD-L1 antibody
STJ130022	St John's Laboratory	50 µl	EUR 385.2
Description: Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies.

Anti-PD-L1 antibody
STJ130023	St John's Laboratory	50 µl	EUR 385.2
Description: Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies.

Anti-PD-L1 antibody
STJ130024	St John's Laboratory	50 µl	EUR 385.2
Description: Programmed death-ligand 1 (PD-L1) is a 40kDa type 1 transmembrane protein that suppresses immune system. PD-L1 is expressed in hematopoietic and nonhematopoietic cells including T cells and B cells and various types of tumor cells. PD-L1 binds to its receptor Programmed death 1 (PD1). During infection or inflammation, PD1PD-L1 interaction is important for preventing autoimmunity. In tumor microenvironments, PD1-PD-L1 interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human cancers. In recent years, PDL1 has become an important biomarker and immunotherapy target for many types of malignancies.

Anti-PD-L1 antibody
STJ180217	St John's Laboratory	0.1 ml	EUR 336

Anti-PD-L1 antibody
STJ180383	St John's Laboratory	0.1 ml	EUR 295.2

Anti-PD-L1 antibody
STJ190082	St John's Laboratory	200 µl	EUR 236.4
Description: Unconjugated Mouse monoclonal to PD-L1 (AS1A7)

Anti-PD-L1 Antibody
A1454-100	Biovision	each	EUR 405.6

Anti-PD-L1 Antibody
A1454-30T	Biovision	each	EUR 175.2

anti- PD-L1/CD274 antibody
FNab06280	FN Test	100µg	EUR 606.3
Description: Antibody raised against PD-L1/CD274

anti- PD-L1/CD274 antibody
FNab06281	FN Test	100µg	EUR 658.5
Description: Antibody raised against PD-L1/CD274

Anti-PD-L1/CD274 Antibody
PA1851	BosterBio	100ug/vial	EUR 352.8

Anti-PD-L1/CD274 antibody
PAab06280	Lifescience Market	100 ug	EUR 426

Anti-PD-L1/CD274 Antibody
PB9154	BosterBio	100ug/vial	EUR 352.8

Anti-PD-L1/CD274 Antibody
PB9994	BosterBio	100ug/vial	EUR 352.8

Anti-CD274 / PD-L1 antibody
STJ70646	St John's Laboratory	100 µg	EUR 430.8

Anti-PD-L1 Antibody (IHC411)
A1549-50	Biovision	each	EUR 222

Anti-PD-L1, PE-labeled
71128-1	BPS Bioscience	50 µg	EUR 355
Description: R-Phycoerythrin-labeled anti-PD-L1 recombinant murine/human antibody recognizing the PD-1 binding region of human PD-L1. This antibody does not cross-react with mouse PD-L1, but does cross-react with monkey (M. fascicularis) PD-L1. It has not been tested with other species.

Anti-PD-L1, PE-labeled
71128-2	BPS Bioscience	100 µg	EUR 510
Description: R-Phycoerythrin-labeled anti-PD-L1 recombinant murine/human antibody recognizing the PD-1 binding region of human PD-L1. This antibody does not cross-react with mouse PD-L1, but does cross-react with monkey (M. fascicularis) PD-L1. It has not been tested with other species.

PD-L1 Antibody
49251-100ul	SAB	100ul	EUR 399.6

PD-L1 Antibody
49251-50ul	SAB	50ul	EUR 286.8

PD-L1 Peptide
46-156P	ProSci	0.1 mg	EUR 405.6
Description: CD274 / PD-L1 Peptide

PD-L1 Antibody
4059-002mg	ProSci	0.02 mg	EUR 206.18
Description: PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, PD-L1 modulates the activation threshold of T-cells and limits T-cell effector response (1). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (2,3). Through a yet unknown activating receptor, it may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (4).

PD-L1 Antibody
4059-01mg	ProSci	0.1 mg	EUR 523.7
Description: PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, PD-L1 modulates the activation threshold of T-cells and limits T-cell effector response (1). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (2,3). Through a yet unknown activating receptor, it may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (4).

PD-L1 Peptide
4059P	ProSci	0.05 mg	EUR 197.7
Description: (IN) PD-L1 peptide

PD-L1 Protein
20-abx261703	Abbexa	EUR 4101.60 EUR 393.60 EUR 276.00	1 mg 20 ug 5 ug

PD-L1 Protein
20-abx263458	Abbexa	EUR 1930.80 EUR 393.60 EUR 276.00	100 ug 10 ug 2 µg

PD-L1 Antibody
P1013-01m	SAB	0.1m	EUR 224.4

PD-L1 Antibody
P1013-1ml	SAB	1ml	EUR 807.6

PD-L1, CD274
E6TA00108	EnoGene	0.1mg	EUR 411.6

PD-L1 Antibody
R31573	NSJ Bioreagents	100 ug	EUR 419

PD-L1 Antibody
R33263-100UG	NSJ Bioreagents	100 ug	EUR 399

PD-L1 (CD274)
100443-1	BPS Bioscience	100 µg	EUR 320
Description: Human secreted Programmed Cell Death 1 Ligand 1 (PD-L1) protein, also known as CD274, PDCD1L1, and B7 homolog 1 (B7-H1), GenBank Accession No. NM_014143, a.a. 19-239, expressed in an E. coli expression system. MW = 25 kDa.

PD-L1 (CD274)
100443-2	BPS Bioscience	1 mg	EUR 2720
Description: Human secreted Programmed Cell Death 1 Ligand 1 (PD-L1) protein, also known as CD274, PDCD1L1, and B7 homolog 1 (B7-H1), GenBank Accession No. NM_014143, a.a. 19-239, expressed in an E. coli expression system. MW = 25 kDa.

PD-1/PD-L1 inhibitor 2
B6023-25	ApexBio	25 mg	EUR 525.6
Description: PD-1/PD-L1 inhibitor 2 is a PD-1/PD-L1 interaction inhibitor.

PD-1/PD-L1 inhibitor 2
B6023-5	ApexBio	5 mg	EUR 205.2
Description: PD-1/PD-L1 inhibitor 2 is a PD-1/PD-L1 interaction inhibitor.

PD-1/PD-L1 inhibitor 1
B6172-25	ApexBio	25 mg	EUR 543.6
Description: IC50: 0.006-0.10 ?MPD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor.Plenty of studies show that blocking the PD-1/PD-Ll interactions can lead to the restorage and augment of T cell activation in many systems.

PD-1/PD-L1 inhibitor 1
B6172-5	ApexBio	5 mg	EUR 201.6
Description: IC50: 0.006-0.10 ?MPD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor.Plenty of studies show that blocking the PD-1/PD-Ll interactions can lead to the restorage and augment of T cell activation in many systems.

PD-1/PD-L1 Inhibitor 2
B1050-25	Biovision	each	EUR 679.2

PD-1/PD-L1 Inhibitor 2
B1050-5	Biovision	each	EUR 242.4

PD-1/PD-L1 Inhibitor 1
B1213-25	Biovision	each	EUR 679.2

PD-1/PD-L1 Inhibitor 1
B1213-5	Biovision	each	EUR 222

Anti-CD274 / PD-L1, Biotinylated antibody
STJ73200	St John's Laboratory	100 µg	EUR 430.8

Anti-PD-L1 (Atezolizumab), humanized Antibody
A1305-100	Biovision	each	EUR 601.2

Anti-PD-L1 (CD274) Neutralizing Antibody
71213	BPS Bioscience	100 µg	EUR 505
Description: Neutralizing recombinant chimeric murine/human monoclonal antibody recognizing the extracellular domain of PD-L1 and blocking the binding of PD-L1 to PD-1. This antibody has been shown to cross-react with mouse PD-L1. No other species have been tested.

PD-L1 Conjugated Antibody
C49251	SAB	100ul	EUR 476.4

PD-L1 (CD274) siRNA
20-abx910978	Abbexa	EUR 661.20 EUR 878.40	15 nmol 30 nmol

PD-L1 (CD274) siRNA
20-abx910979	Abbexa	EUR 661.20 EUR 878.40	15 nmol 30 nmol

PD-L1 Recombinant Protein
91-293	ProSci	0.05 mg	EUR 405.6
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.

PD-L1 Recombinant Protein
92-486	ProSci	0.05 mg	EUR 374.1
Description: Mouse Programmed cell death 1 ligand 1(Cd274，PD-L1), is a member of the growing B7 family of immune proteins.It involved in the costimulatory signal essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production.B7-H1 has been identified as one of two ligands for programmed death1 (PD1), a member of the CD28 family of immunoreceptors. B7-H1 is constitutively expressed in several organs such as heart, skeletal muscle B7-H1 expression is upregulated in a small fraction of activated T and B cells and a much larger fraction of activated monocytes. The costimulatory function of B7-H1 is critical for enhancing maturation and differentiation of T-cells in lymphoid organs.B7-H1 expression is also induced in dendritic cells and keratinocytes after IFN gamma stimulation. Interaction of B7-H1 with PD1 results in inhibition of TCR-mediated proliferation and cytokine production. The B7-H1:PD1 pathway is involved in the negative regulation of some immune responses and may play an important role in the regulation of peripheral tolerance.

PD-L1 Recombinant Protein
92-487	ProSci	0.05 mg	EUR 374.1
Description: Mouse Programmed cell death 1 ligand 1(Cd274，PD-L1), is a member of the growing B7 family of immune proteins.It involved in the costimulatory signal essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production.B7-H1 has been identified as one of two ligands for programmed death1 (PD1), a member of the CD28 family of immunoreceptors. B7-H1 is constitutively expressed in several organs such as heart, skeletal muscle B7-H1 expression is upregulated in a small fraction of activated T and B cells and a much larger fraction of activated monocytes. The costimulatory function of B7-H1 is critical for enhancing maturation and differentiation of T-cells in lymphoid organs.B7-H1 expression is also induced in dendritic cells and keratinocytes after IFN gamma stimulation. Interaction of B7-H1 with PD1 results in inhibition of TCR-mediated proliferation and cytokine production. The B7-H1:PD1 pathway is involved in the negative regulation of some immune responses and may play an important role in the regulation of peripheral tolerance.

PD-L1 Rabbit pAb
A11273-100ul	Abclonal	100 ul	EUR 369.6

PD-L1 Rabbit pAb
A11273-200ul	Abclonal	200 ul	EUR 550.8

PD-L1 Rabbit pAb
A11273-20ul	Abclonal	20 ul	EUR 219.6

PD-L1 Rabbit pAb
A11273-50ul	Abclonal	50 ul	EUR 267.6

Mouse PD-L1 Antibody
32903-05111	AssayPro	150 ug	EUR 313.2

PD-L1 Blocking Peptide
20-abx161326	Abbexa	EUR 326.40 EUR 493.20	1 mg 5 mg

PD-L1 Rabbit mAb
A20270	Abclonal	20 μL	EUR 18

PD-L1 Rabbit mAb
A20344	Abclonal	20 μL	EUR 18

PD-L1 Rabbit pAb
A1645-100ul	Abclonal	100 ul	EUR 369.6

PD-L1 Rabbit pAb
A1645-200ul	Abclonal	200 ul	EUR 550.8

PD-L1 Rabbit pAb
A1645-20ul	Abclonal	20 ul	EUR 219.6

PD-L1 Rabbit pAb
A1645-50ul	Abclonal	50 ul	EUR 267.6

PD-L1 Recombinant Protein
92-599	ProSci	0.05 mg	EUR 437.1
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.

PD-L1 Recombinant Protein
92-625	ProSci	0.05 mg	EUR 437.1
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.

PD-L1 Recombinant Protein
92-671	ProSci	0.05 mg	EUR 437.1
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.

PD-L1 Recombinant Protein
96-937	ProSci	0.1 mg	EUR 619.8
Description: Programmed cell death 1 ligand 1 (PD-L1) is also known as cluster of differentiation (CD274) or B7 homolog 1 (B7-H1), is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses. B7-H1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. PD-L1 is highly expressed in the heart, skeletal muscle, placenta and lung and weakly expressed in the thymus, spleen, kidney and liver. PD-L1 is expressed on activated T-cells, B-cells, dendritic cells, keratinocytes and monocytes. PD-L1 is up-regulated on T- and B-cells, dendritic cells, keratinocytes and monocytes after LPS and IFNG activation and up-regulated in B-cells activated by surface Ig cross-linking. PD-L1 involve in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner.

PD-L1 Recombinant Protein
97-020	ProSci	0.1 mg	EUR 714.3
Description: Programmed cell death 1 ligand 1 (PDL1) is also known as B7-H, B7H1, MGC142294, MGC142296, PD-L1, PDCD1L1 and PDCD1LG1,which is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses.PDL1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. This protein is broadly expressed in the majority of peripheral tissues as well as hematopoietic cells. Interaction between PDL1 and its receptors belonging to the CD28 family of molecules provide both stimulatory and inhibitory signals in regulating T cell activation and tolerance. PDL1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression.

B7-H1/PD-L1
E21-315	EnoGene	10ug	EUR 411.6

PD-L1 Antibody [F6A9]
SD8639-002mg	ProSci	0.02 mg	EUR 253.22
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts.

PD-L1 Antibody [F6A9]
SD8639-01mg	ProSci	0.1 mg	EUR 723.62
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts.

PD-L1 Antibody [F2G2]
SD8641-002mg	ProSci	0.02 mg	EUR 253.22
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts.

PD-L1 Antibody [F2G2]
SD8641-01mg	ProSci	0.1 mg	EUR 723.62
Description: PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells. This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts.

PD-1:PD-L1 Homogeneous Assay Kit
72014	BPS Bioscience	384 rxns.	EUR 1070
Description: The PD-1:PD-L1 Homogeneous Assay Kit is designed to measure the_x000D_inhibition of PD-1 binding to PD-L1. With this kit, only three simple steps on a microtiter_x000D_plate are required. First, a sample containing PD-1 and an inhibitor of choice is incubated with_x000D_the biotinylated PD-L1 for 60 minutes. Next, acceptor beads are added, then donor beads,_x000D_followed by reading the Alpha-counts.

PD-1:PD-L1 TR-FRET Assay
72032	BPS Bioscience	96 rxns.	EUR 745
Description: The PD-1:PD-L1 TR-FRET Assay is designed to measure the inhibition of PD-1 binding to PD-L1 in a homogeneous 96 reaction format. This FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; a sample containing europium-labeled (Eu) PD-1, dye-labeled acceptor, biotin-labeled PD-L1, and an inhibitor is incubated for two hours. Then, the fluorescence intensity is measured using a fluorescence reader.

PD-1:PD-L1 TR-FRET Assay
72038	BPS Bioscience	384 rxns.	EUR 845
Description: The PD-1:PD-L1 TR-FRET Assay is designed to measure the inhibition of PD-1 binding to PD-L1 in a homogeneous 384 reaction format. This FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; a sample containing europium-labeled (Eu) PD-1, dye-labeled acceptor, biotin-labeled PD-L1, and an inhibitor is incubated for two hours. Then, the fluorescence intensity is measured using a fluorescence reader.

Rabbit Anti-Human PD-L1 monoclonal antibody
CABT-BL8451	Creative Diagnostics	100 ul	EUR 795.6

Rabbit Anti-Human PD-L1 monoclonal antibody
CABT-BL8452	Creative Diagnostics	100 ul	EUR 795.6

Mouse Anti-Human CD274 (PD-L1) mAb
CM025-100ug	SAB	100ug	EUR 337.2

Mouse Anti-Human CD274 (PD-L1) mAb
CM025-25ug	SAB	25ug	EUR 198

Mouse Anti-Human CD274 (PD-L1) mAb
CM026-100ug	SAB	100ug	EUR 337.2

Mouse Anti-Human CD274 (PD-L1) mAb
CM026-25ug	SAB	25ug	EUR 198

Mouse Anti-Human CD274 (PD-L1) mAb
CM027-100ug	SAB	100ug	EUR 267.6

Mouse Anti-Human CD274 (PD-L1) mAb
CM027-25ug	SAB	25ug	EUR 181.2

Anti-PD-L1 (Durvalumab), Human IgG1 Antibody
A2109-100	Biovision	100 µg	EUR 612

Anti-PD-L1 (Avelumab), Human IgG1 Antibody
A2152-100	Biovision	100 µg	EUR 612

Anti-PD-L1/B7-H1/CD274 Antibody
A00109	BosterBio	100ug/vial	EUR 352.8

Polyclonal Goat Anti-CD274 / PD-L1 Antibody
APG00067G	Leading Biology	0.1mg	EUR 580.8
Description: A polyclonal antibody raised in Goat that recognizes and binds to Human Goat Anti-CD274 / PD-L1 . This antibody is tested and proven to work in the following applications:

Mouse Anti-Human CD274 (PD-L1) mAb
P1062-25ug	SAB	25ug	EUR 181.2

Anti-PD-L1 (CD274) Rabbit Monoclonal Antibody
M00109	BosterBio	100ug/vial	EUR 476.4
Description: Rabbit Monoclonal PD-L1 (CD274) Antibody. Validated in IHC-P, WB and tested in Human, Mouse, Rat.

Anti-PD-L1 Monoclonal Antibody (Clone: ABM5F25)
A1537-50	Biovision	each	EUR 366

Anti-PD-L1 Neutralizing Antibody, Biotin-labeled
71214	BPS Bioscience	100 µg	EUR 510
Description: Purified, recombinant, chimeric murine/human anti-PD-L1 (IgG1) antibody with C-terminal Avi-tag, expressed in HEK293 cells. Purified antibody was enzymatically biotinylated using Avitag™ technology. This antibody reacts with human PD-L1 and cross-reacts with mouse PD-L1. It has not been tested for cross-reactivity with other species.

Ribosome-inactivating protein PD-L1/PD-L2 Antibody
1-CSB-PA306294LA01PJJ	Cusabio	EUR 380.40 EUR 402.00	100ug 50ug
Description: A polyclonal antibody against Ribosome-inactivating protein PD-L1/PD-L2. Recognizes Ribosome-inactivating protein PD-L1/PD-L2 from Phytolacca dioica. This antibody is Unconjugated. Tested in the following application: ELISA

Ribosome-inactivating protein PD-L1 / PD-L2 Antibody
20-abx319445	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

PD-1[Biotinylated]:PD-L1 Homogeneous Assay Kit
72028	BPS Bioscience	384 rxns.	EUR 1070
Description: The PD-1[Biotinylated]:PD-L1 Homogeneous Assay Kit is designed to measure_x000D_the inhibition of PD-1 binding to PD-L1. The PD-1[Biotinylated]:PD-L1 Homogeneous Assay Kit_x000D_comes in a convenient AlphaLISA® format with purified biotinylated PD-1, FLAG-tagged PD-L1,_x000D_and assay buffer to perform a total of 384 reactions. With this kit, only three simple steps on a_x000D_microtiter plate are required. First, a sample containing biotinylated PD-1 and an inhibitor of_x000D_choice is incubated with the FLAG-tagged PD-L1 for 60 minutes. Next, acceptor beads are_x000D_added, then donor beads, followed by reading the Alpha-counts.

PD-L1 Fc Recombinant Protein
40-696	ProSci	20 ug	EUR 311.1
Description: Programmed death-ligand 1 (PD-L1), or B7-H1, is a transmembrane, co-stimulatory ligand of programmed cell death protein 1 (PD-1) that, along with B7-1 and B7-2, belongs to the B7 family and immunoglobulin superfamily. Though more notably expressed on activated T cells, B cells, myeloid cells, and a subset of thymocytes, PD-L1 is also expressed constitutively by nonlymphoid, parenchymal organs, including the heart, placenta, skeletal muscle, and lung; with the marked exception of the small intestine. As a member of the B7 family, PD-L1 plays a principal role in immunity: suppressing immune response against autoantigens and tumors, maintaining T cell homeostasis, maintaining peripheral immune tolerance, and regulating T-cell-mediated cytokine secretion. Unlike B7-1 and B7-2, PD-L1 has not been shown to influence immunity through interaction with CD28, CTLA-4 or ICOS, but rather through interaction with PD-1, a weak structural homolog of CTLA-4 that belongs to the same superfamily. Involvement of PD-1 suggests an inhibitory function during T cell activation; however, evidence has demonstrated PD-L1’s conflicting responsibility for both the stimulation and inhibition of T-cell-mediated cytokine synthesis. While T cell co-stimulation with PD-L1 induces proliferation and the secretion of IL-10 and IFN-γ, muscle cell expression of PD-L1 has been shown to inhibit function of CD4 and CD8 T cells by down-regulating cytokine secretion and the expression of T cell activation markers. Augmented expression of PD-L1 has been linked to the inhibition of antitumor immune response in cancer, and the up-regulation of IL-10 production in HIV-infection, resulting in increased susceptibility of antigen-specific T cells to apoptosis. CHO cell-derived Recombinant Human PD-L1 Fc is a glycosylated, disulfide-linked homodimer of 906 amino acid residues whose monomer consists of the 220-amino-acid length extracellular portion of PD-L1 fused to the 231-amino-acid length Fc portion of human IgG1 by two glycines. The calculated molecular weight of CHO cell-derived Recombinant Human PD-L1 Fc is 102.6 kDa, however, due to glycosylation, it migrates at an apparent molecular weight of approximately 160-170 kDa by SDS-PAGE analysis under non-reducing conditions.

PD-L1/B7-H1/CD274
E21-J88	EnoGene	10ug	EUR 411.6

Human PD-L1 Elisa Kit
QY-E05642	Qayee Biotechnology	96T	EUR 433.2

PD-L1 /CD274, Human Recombinant
P1023-10	Biovision	each	EUR 301.2

PD-L1 /CD274, Human Recombinant
P1023-50	Biovision	each	EUR 823.2

Mouse Anti-Human CD274 (PD-L1) mAbConjugated Antibody
CCM025	SAB	100ul	EUR 476.4

Anti-PD-L1-Fab Avi-Tag, Biotin-Labeled
11032	BPS Bioscience	100 µg	EUR 510
Description: PD-L1 Neutralizing Antibody FAB fragment, recombinant humanized monoclonal, recognizing the extracellular domain of human PD-L1 and blocking the binding of PD-L1 to PD-1. This antibody FAB has been shown to cross-react with mouse PD-L1. No other species have been tested.

Phytolacca dioica Ribosome-inactivating protein PD-L1/PD-L2
1-CSB-EP306294PJJ	Cusabio	EUR 733.20 EUR 370.80 EUR 2192.40 EUR 1126.80 EUR 1461.60 EUR 476.40	100ug 10ug 1MG 200ug 500ug 50ug
Description: Recombinant Phytolacca dioica Ribosome-inactivating protein PD-L1/PD-L2 expressed in E.coli

Ribosome-inactivating protein PD-L1 / PD-L2 Antibody (HRP)
20-abx319446	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Ribosome-inactivating protein PD-L1 / PD-L2 Antibody (FITC)
20-abx319447	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Ribosome-inactivating protein PD-L1 / PD-L2 Antibody (Biotin)
20-abx319448	Abbexa	EUR 493.20 EUR 2214.00 EUR 718.80 EUR 218.40 EUR 360.00	100 ug 1 mg 200 ug 20 ug 50 ug

Ribosome-Inactivating Protein PD-L1/PD-L2 Polyclonal Antibody
A64216-020	EpiGentek	20 ul	EUR 117.7

Ribosome-Inactivating Protein PD-L1/PD-L2 Polyclonal Antibody
A64216-050	EpiGentek	50 ul	EUR 302.5

Ribosome-Inactivating Protein PD-L1/PD-L2 Polyclonal Antibody
A64216-100	EpiGentek	100 ul	EUR 423.5

Ribosome-Inactivating Protein PD-L1/PD-L2 Polyclonal Antibody
A64216	EpiGentek	EUR 684.66 EUR 117.70 EUR 302.50 EUR 423.50	100 µg 20 ul 50 ul 100 ul

PD-1:PD-L1[Biotinylated] Inhibitor Screening Assay Kit
72003	BPS Bioscience	96 rxns.	EUR 1235
Description: The PD-1:PD-L1[Biotinylated] Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of this signaling. The key to this kit is the high sensitivity of detection of biotin-labeled PD-L1 by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, PD-1 is coated on a 96-well plate. Next, PD-L1 is incubated with PD-1 on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a chemiluminescence reader.

PD-1[Biotinylated]:PD-L1 Inhibitor Screening Assay Kit
72005	BPS Bioscience	96 rxns.	EUR 840
Description: The PD-L1 Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of this signaling. The key to this kit is the high sensitivity of detection of biotin-labeled PD-1 by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, PD-L1 is coated on a 96-well plate. Next, PD-1 is incubated with PD-L1 on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a chemiluminescence reader.

PD-1[Biotinylated]: PD-L1 Inhibitor Screening Assay Kit
79523	BPS Bioscience	384 rxns.	EUR 1070
Description: Cell signaling through the PD-1 receptor upon binding the PD-L1 ligand attenuates immune responses and is exploited by both tumors and viruses. The PD-1[Biotinylated]: PD-L1 Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of this signaling. This kit comes in a convenient 384-well format with biotin-labeled PD-1, purified PD-L1, streptavidin-labeled HRP, and assay buffer for 400 binding reactions. The key to this kit is the high sensitivity of detection of biotin-labeled PD-1 by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, PD-L1 is coated on a 384-well plate. Next, PD-1 is incubated with PD-L1 on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a chemiluminescence reader.

PD-1:PD-L1/PD-L2 Cell-Based Inhibitor Screening Assay Kit
60800	BPS Bioscience	96 rxns.	EUR 1070
Description: The PD-1/PD-L1 Inhibitor Screening Cell-Based Assay is a bioluminescent cell-based assay that can be used to screen and profile inhibitors of PD-1:PD-L1 or PD-1:PD-L2 interaction. The assay consists of two main components:_x000D_ • PD-1 Effector cells (PD-1/NFAT reporter-Jurkat cells): Reporter Jurkat T cells expressing firefly luciferase gene under the control of NFAT response elements and also constitutively expressing human PD-1. These cryopreserved cells are provided in a thaw-and-use format that does not require cell propagation._x000D_ • _x000D_Expression vectors for TCR activator, human PD-L1, and human PD-L2: Transfection-ready vectors are used to transfect cells to create the target cells that overexpress PD-L1 or PD-L2 and an engineered cell surface T cell receptor (TCR) activator._x000D_

PD-L1 / B7-H1 Recombinant Protein
11-345	ProSci	0.1 mg	EUR 714.3
Description: Programmed cell death 1 ligand 1 (PDL1) is also known as B7-H, B7H1, MGC142294, MGC142296, PD-L1, PDCD1L1 and PDCD1LG1,which is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses.PDL1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. This protein is broadly expressed in the majority of peripheral tissues as well as hematopoietic cells. Interaction between PDL1 and its receptors belonging to the CD28 family of molecules provide both stimulatory and inhibitory signals in regulating T cell activation and tolerance. PDL1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression.

Mouse PD-L1 Antibody (Biotin Conjugate)
32903-05121	AssayPro	150 ug	EUR 442.8

[KO Validated] PD-L1 Rabbit mAb
A19135	Abclonal	20 μL	EUR 18

[KO Validated] PD-L1 Rabbit mAb
A19135-100ul	Abclonal	100 ul	EUR 492

[KO Validated] PD-L1 Rabbit mAb
A19135-200ul	Abclonal	200 ul	EUR 685.2

[KO Validated] PD-L1 Rabbit mAb
A19135-20ul	Abclonal	20 ul	EUR 265.2

[KO Validated] PD-L1 Rabbit mAb
A19135-50ul	Abclonal	50 ul	EUR 344.4

PD-L1, His (HEK293-expressed), Human
HY-P7398	MedChemExpress	100ug	EUR 349.2

PD-L1 Antibody / B7-H1 / CD274
F55054-0.1ML	NSJ Bioreagents	0.1ml	EUR 399

PD-L1 Antibody / B7-H1 / CD274
R32479	NSJ Bioreagents	100 ug	EUR 419

PD-L1 Antibody / B7-H1 / CD274
R32579	NSJ Bioreagents	100 ug	EUR 419

PD-L1 Antibody / B7-H1 / CD274
V7822-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274
V7822-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274
V7822SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274
V7823-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274
V7823-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274
V7823SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274
V7974-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274
V7974-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274
V7974SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274
V7988-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. Engagement of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases.

PD-L1 Antibody / B7-H1 / CD274
V7988-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. Engagement of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases.

PD-L1 Antibody / B7-H1 / CD274
V7988SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. Engagement of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. The constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases.

PD-L1 Antibody / B7-H1 / CD274
V8009-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274
V8009-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274
V8009SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274
V8067-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer’s ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274
V8067-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer’s ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274
V8067SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer’s ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274
V3955-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. recruitment of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. Constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases.

PD-L1 Antibody / B7-H1 / CD274
V3955-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. recruitment of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. Constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases.

PD-L1 Antibody / B7-H1 / CD274
V3955BTN	NSJ Bioreagents	500 ul	EUR 499
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274
V3955PE-100T	NSJ Bioreagents	100 Tests	EUR 499
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274
V3955SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: Engagement of CD28 by B7-1 (CD80) or B7-2 (CD86) in the presence of antigen promotes T-cell proliferation, cytokine production, differentiation of effector T-cells and the induction of BCLX, a promoter of T-cell survival. recruitment of CTLA4 by B7-1 or B7-2, on the other hand, may inhibit proliferation and interleukin-2 (IL-2) production. PD-L1 is 290-amino acid type I transmembrane protein, which is 20% and 15% identical to B7-1 and B7-2, respectively, has immunoglobulin V-like and C-like domains and a 30-amino acid cytoplasmic tail. PD-L1 does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). IL-2, although produced in small amounts, is required for the effect of PD-L1 co-stimulation. PD-L2 protein contains a signal sequence, IgV- and IgC-like domains, a transmembrane region and a cytoplasmic region. Constitutive expression of PD-L1 and PD-L2 on parenchymal cells of heart, lung and kidney suggests that the PD-1-PD-L system could provide unique negative signaling to help prevent autoimmune diseases.

PD-L1/CD274 (Human) ELISA Kit
K4155-100	Biovision	each	EUR 966

PD-L1 Antibody / B7-H1 / CD274
V8598-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274
V8598-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274
V8598SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274
V8640-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274
V8640-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274
V8640SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancer s ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274
V8641-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancers ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274
V8641-20UG	NSJ Bioreagents	20 ug	EUR 219
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancers ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274
V8641SAF-100UG	NSJ Bioreagents	100 ug	EUR 499
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells. Expression of the protein is seen during pregnancy where it has a role in suppressing the immune system. PD-L1 induces an inhibitory signal in activated T-cells and promotes T-cell apoptosis. It is overexpressed in a number of different cancers where it is believed to play a significant role in the cancers ability to evade the immune system.

PD-L1 Antibody / B7-H1 / CD274
V9155-100UG	NSJ Bioreagents	100ug	EUR 499
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells.

PD-L1 Antibody / B7-H1 / CD274
V9155-20UG	NSJ Bioreagents	20ug	EUR 219
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells.

PD-L1 Antibody / B7-H1 / CD274
V9155SAF-100UG	NSJ Bioreagents	100ug	EUR 499
Description: PD-L1 is a checkpoint regulator in immune cells, it is expressed on immune or non-hematopoietic cells.

PD-L1 - CHO Recombinant Cell Line
60543	BPS Bioscience	2 vials	EUR 5205
Description: Recombinant CHO-K1 cells constitutively expressing human PD-L1 (Programmed Cell Death 1 Ligand 1, CD274, B7 homolog 1 (B7- H1), GenBank accession #NM_014143).

Mouse PD-L1 (CD274), Fc fusion
71117-1	BPS Bioscience	50 µg	EUR 215
Description: Mouse secreted Programmed Cell Death 1_x000D_Ligand 1 (PD-L1)-Fc fusion protein, also_x000D_known as CD274 and B7 homolog 1 (B7-_x000D_H1), GenBank Accession No. NM_021893,_x000D_a.a. 19-238, fused at the C-terminus to the_x000D_Fc portion of mouse IgG2a, expressed in a_x000D_HEK293 cell expression system. MW = 51.8_x000D_kDa.

Mouse PD-L1 (CD274), Fc fusion
71117-2	BPS Bioscience	100 µg	EUR 325
Description: Mouse secreted Programmed Cell Death 1_x000D_Ligand 1 (PD-L1)-Fc fusion protein, also_x000D_known as CD274 and B7 homolog 1 (B7-_x000D_H1), GenBank Accession No. NM_021893,_x000D_a.a. 19-238, fused at the C-terminus to the_x000D_Fc portion of mouse IgG2a, expressed in a_x000D_HEK293 cell expression system. MW = 51.8_x000D_kDa.

PD-L1 CRISPR/Cas9 Lentivirus (Integrating)
78057	BPS Bioscience	500 µl x 2	EUR 795
Description: The binding of Programmed Cell Death Protein 1 (PD-1), a receptor expressed on activated T-cells, to its ligands, PD-L1 and PD-L2, negatively regulates immune responses. The PD-1 ligands are found on most cancers, and the PD-1:PD-L1/2 interaction inhibits T-cell activity and allows cancer cells to escape immune surveillance. The PD-1:PD-L1/2 pathway is also involved in regulating autoimmune responses, making these proteins promising therapeutic targets for a number of cancers, as well as multiple sclerosis, arthritis, lupus, and type I diabetes._x000D_The PD-L1 CRISPR Lentiviruses are replication incompetent, HIV-based, VSV-G pseudo-typed lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a CRISPR/Cas9 gene driven by an EF1a promoter, along with 4 sgRNA (single guide RNA) targeting human PD-L1 (Programmed Cell Death 1 Ligand 1, CD274, B7 homolog 1 (B7-H1), GenBank accession #NM_021893) driven by a U6 promoter (Figures 1 and 2)._x000D_The integrating lentivirus integrates randomly into the cell's genome to express both the Cas9 and sgRNA. Puromycin selection increases the knockout efficiency by forcing high expression levels of both Cas9 and the sgRNA, and can be used with the integrating lentivirus to quickly and easily achieve high knockdown efficiencies in a cell pool. Efficiencies also depend on the cell type and the gene of interest._x000D_

Mouse Anti-Human PD-L1 monoclonal antibody, clone JID522
CABT-L2928-100uL500uL	Creative Diagnostics	100 uL, 500 uL	EUR 602.4

Mouse Anti-PD-L1 IgG Monoclonal Antibody, Clone 3A9F12
7122	Chondrex	1 mg/ml x 0.1 ml	EUR 406.26
Description: Mouse Anti-PD-L1 IgG Monoclonal Antibody

Anti-CD274/ PD-L1 Antibody [10F.9G2], Unconjugated-100ug
QAB95-100ug	EnQuireBio	100ug	EUR 229.2

Anti-CD274/ PD-L1 Antibody [10F.9G2], PE-100ug
QAB95-PE-100ug	EnQuireBio	100ug	EUR 259.2

Anti-CD274/ PD-L1 Antibody [10F.9G2], PE-25ug
QAB95-PE-25ug	EnQuireBio	25ug	EUR 147.6

Anti-PD-L1 (CD274) (B7-H1), Rabbit Monoclonal Antibody
A1824-50	Biovision	each	Ask for price

Ribosome-inactivating protein PD-L1/PD-L2 Antibody, HRP conjugated
1-CSB-PA306294LB01PJJ	Cusabio	EUR 380.40 EUR 402.00	100ug 50ug
Description: A polyclonal antibody against Ribosome-inactivating protein PD-L1/PD-L2. Recognizes Ribosome-inactivating protein PD-L1/PD-L2 from Phytolacca dioica. This antibody is HRP conjugated. Tested in the following application: ELISA

Ribosome-inactivating protein PD-L1/PD-L2 Antibody, FITC conjugated
1-CSB-PA306294LC01PJJ	Cusabio	EUR 380.40 EUR 402.00	100ug 50ug
Description: A polyclonal antibody against Ribosome-inactivating protein PD-L1/PD-L2. Recognizes Ribosome-inactivating protein PD-L1/PD-L2 from Phytolacca dioica. This antibody is FITC conjugated. Tested in the following application: ELISA

Ribosome-inactivating protein PD-L1/PD-L2 Antibody, Biotin conjugated
1-CSB-PA306294LD01PJJ	Cusabio	EUR 380.40 EUR 402.00	100ug 50ug
Description: A polyclonal antibody against Ribosome-inactivating protein PD-L1/PD-L2. Recognizes Ribosome-inactivating protein PD-L1/PD-L2 from Phytolacca dioica. This antibody is Biotin conjugated. Tested in the following application: ELISA

PD-1:PD-L1[Biotinylated] Inhibitor Screening Colorimetric Assay Kit
72016	BPS Bioscience	96 rxns.	EUR 1210
Description: Cell signaling through the PD-1 receptor upon binding the PD-L1 ligand_x000D_attenuates immune responses and is exploited by both tumors and viruses. The PD-1:PDL1[Biotinylated] Inhibitor Screening Colorimetric Assay Kit is designed for screening inhibitors of_x000D_PD-L1 ligand binding to PD-1 receptor. The key to this kit is the high affinity of biotin-labeled PD-L1 for streptavidin-HRP._x000D_Only a few simple steps on a microtiter plate are required for the assay. First, PD-1 is coated on_x000D_a 96-well plate. Next, PD-L1 is incubated with PD-1 on the plate. Finally, the plate is treated with_x000D_streptavidin-HRP followed by addition of a colorimetric HRP substrate to produce color, which_x000D_can then be measured using a UV/Vis spectrophotometer microplate reader.

PD-1[Biotinylated]:PD-L1 Inhibitor Screening Colorimetric Assay Kit
72018	BPS Bioscience	96 rxns.	EUR 1095
Description: Cell signaling through the PD-1 receptor upon binding the PD-L1 ligand_x000D_attenuates immune responses and is exploited by both tumors and viruses. The PD-_x000D_1[Biotinylated]:PD-L1 Inhibitor Colorimetric Screening Assay Kit is designed for screening_x000D_inhibitors of PD-1 receptor binding to PD-L1 ligand. This kit comes in a convenient 96-well_x000D_format, with biotin-labeled PD-1, purified PD-L1, streptavidin-labeled HRP, and assay buffer for_x000D_100 binding reactions. The key to this kit is the high affinity of biotin-labeled PD-1 for_x000D_streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First,_x000D_PD-L1 is coated on a 96-well plate. Next, PD-1 is incubated with PD-L1 on the plate. Finally, the_x000D_plate is treated with streptavidin-HRP followed by addition of a colorimetric HRP substrate to_x000D_produce color, which can then be measured using a UV/Vis spectrophotometer microplate_x000D_reader.

Mouse PD-1[Biotinylated]:PD-L1 Inhibitor Screening Assay Kit
72027	BPS Bioscience	96 rxns.	EUR 1300
Description: The Mouse PD-1[Biotinylated]:PD-L1 Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of this signaling. The key to this kit is the high sensitivity of detection of biotin-labeled PD-1 by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, mouse PD-L1 is coated on a 96-well plate. Next, mouse PD-1 is incubated with mouse PD-L1 on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a chemiluminescence reader.

PD-1:PD-L1 Cell-Based Inhibitor Screening Assay Kit
79377	BPS Bioscience	96 rxns.	EUR 645
Description: The PD-1/PD-L1 Inhibitor Screening Cell-Based Assay is a bioluminescent cell-based assay that can be used to screen and profile inhibitors of the PD-1:PD-L1 interaction. The assay consists of two main components:_x000D_• Growth-Arrested PD-1 Effector cells (PD-1/NFAT reporter-Jurkat cells): Reporter Jurkat T cells expressing firefly luciferase gene under the control of NFAT response elements and also constitutively expressing human PD-1. These cryopreserved cells are provided in a thaw-anduse format that does not require cell propagation. These cells are modified not to be expanded and are intended to be used in a single experiment._x000D_• Expression vectors for TCR activator, and Human PD-L1: Transfection-ready vectors are used to transfect cells to create the target cells that overexpress PD-L1 and an engineered cell surface T cell receptor (TCR) activator.

Monkey PD-1:PD-L1[Biotinylated] Inhibitor Screening Assay Kit
79863	BPS Bioscience	96 rxns.	EUR 820
Description: Cell signaling through the PD-1 receptor upon binding the PD-L1 ligand attenuates immune responses and this pathway is exploited by both tumors and viruses. The Monkey PD-1:PD-L1[Biotinylated] Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of this signaling pathway in the animal model cynomolgus monkey (Macaca fascicularis).

Monkey PD-1[Biotinylated]:PD-L1 Inhibitor Screening Assay Kit
79865	BPS Bioscience	96 rxns.	EUR 765
Description: Cell signaling through the PD-1 receptor upon binding the PD-L1 ligand attenuates immune responses and this pathway is exploited by both tumors and viruses. The Monkey PD-1[Biotinylated]:PD-L1 Inhibitor Screening Assay Kit is designed for screening and profiling inhibitors of this signaling pathway in the animal model cynomolgus monkey (Macaca fascicularis). The key to this kit is the high sensitivity of detection of biotin-labeled PD-1 by streptavidin-HRP. Only a few simple steps on a microtiter plate are required for the assay. First, PD-L1 is coated on a 96-well plate. Next, PD-1 is incubated with PD-L1 on the plate. Finally, the plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence, which can then be measured using a chemiluminescence reader.

Rabbit Polyclonal antibody Anti-CRBN
Anti-CRBN	ImmunoStep	50 µg	EUR 418.8

Ribosome-Inactivating Protein PD-L1/PD-L2 Polyclonal Antibody, HRP Conjugated
A64217-050	EpiGentek	50 ul	EUR 302.5

Ribosome-Inactivating Protein PD-L1/PD-L2 Polyclonal Antibody, HRP Conjugated
A64217-100	EpiGentek	100 ul	EUR 423.5

Ribosome-Inactivating Protein PD-L1/PD-L2 Polyclonal Antibody, FITC Conjugated
A64218-050	EpiGentek	50 ul	EUR 302.5

Ribosome-Inactivating Protein PD-L1/PD-L2 Polyclonal Antibody, FITC Conjugated
A64218-100	EpiGentek	100 ul	EUR 423.5

Ribosome-Inactivating Protein PD-L1/PD-L2 Polyclonal Antibody, Biotin Conjugated
A64219-050	EpiGentek	50 ul	EUR 302.5

Ribosome-Inactivating Protein PD-L1/PD-L2 Polyclonal Antibody, Biotin Conjugated
A64219-100	EpiGentek	100 ul	EUR 423.5

Ribosome-Inactivating Protein PD-L1/PD-L2 Polyclonal Antibody, HRP Conjugated
A64217	EpiGentek	EUR 684.66 EUR 302.50 EUR 423.50	100 µg 50 ul 100 ul

Ribosome-Inactivating Protein PD-L1/PD-L2 Polyclonal Antibody, FITC Conjugated
A64218	EpiGentek	EUR 684.66 EUR 302.50 EUR 423.50	100 µg 50 ul 100 ul

Ribosome-Inactivating Protein PD-L1/PD-L2 Polyclonal Antibody, Biotin Conjugated
A64219	EpiGentek	EUR 684.66 EUR 302.50 EUR 423.50	100 µg 50 ul 100 ul

Mouse PD-L1 AssayLite Antibody (FITC Conjugate)
32903-05141	AssayPro	150 ug	EUR 513.6

Mouse PD-L1 AssayLite Antibody (RPE Conjugate)
32903-05151	AssayPro	150 ug	EUR 513.6

Mouse PD-L1 AssayLite Antibody (APC Conjugate)
32903-05161	AssayPro	150 ug	EUR 513.6

Mouse PD-L1 AssayLite Antibody (PerCP Conjugate)
32903-05171	AssayPro	150 ug	EUR 565.2

CD274 [B7-H1/PD-L1] Recombinant Protein
90-429	ProSci	100 ug	EUR 651.3
Description: Programmed death ligand 1 (PD-L1, B7-H1 or CD274) is a member of the growing B7 family of immune proteins that provide signals for both stimulating and inhibiting T cell activation. CD274 has been identified as one of two ligands for programmed death 1 (PD-1), a member of the CD28 family of immunoreceptors. CD274 is widely expressed in several organs such as heart, skeletal muscle, placenta and lung, and in lower amounts in thymus, spleen, kidney and liver. CD274 expression is upregulated in a small fraction of activated T and B cells and a much larger fraction of activated monocytes. CD274 expression is also induced in dendritic cells and keratinocytes after IFN-gamma stimulation. CD274 expression is also upregulated in a variety of tumor cell lines. Interaction of CD274 with PD-1 results in inhibition of TCR mediated proliferation and cytokine production, suggesting an inhibitory role in regulating immune responses. The CD274 - PD-1 pathway is involved in the negative regulation of some immune responses and may play an important role in the regulation of peripheral tolerance.

CD274 [B7-H1/PD-L1] Recombinant Protein
90-431	ProSci	100 ug	EUR 651.3
Description: Programmed death ligand 1 (PD-L1, B7-H1 or CD274) is a member of the growing B7 family of immune proteins that provide signals for both stimulating and inhibiting T cell activation. CD274 has been identified as one of two ligands for programmed death 1 (PD-1), a member of the CD28 family of immunoreceptors. CD274 is widely expressed in several organs such as heart, skeletal muscle, placenta and lung, and in lower amounts in thymus, spleen, kidney and liver. CD274 expression is upregulated in a small fraction of activated T and B cells and a much larger fraction of activated monocytes. CD274 expression is also induced in dendritic cells and keratinocytes after IFN-gamma stimulation. CD274 expression is also upregulated in a variety of tumor cell lines. Interaction of CD274 with PD-1 results in inhibition of TCR mediated proliferation and cytokine production, suggesting an inhibitory role in regulating immune responses. The CD274 - PD-1 pathway is involved in the negative regulation of some immune responses and may play an important role in the regulation of peripheral tolerance.

Polyclonal B7-H1 / PD-L1 / CD274 Antibody
APR03374G	Leading Biology	0.05ml	EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human B7-H1 / PD-L1 / CD274 . This antibody is tested and proven to work in the following applications:

PD-L1/B7-H1/CD274 (C-mFc)
E21-M06	EnoGene	10ug	EUR 411.6

PD-L1/B7-H1/CD274 (C-Flag)
E21-M33	EnoGene	10ug	EUR 411.6

PD-L1/B7-H1/CD274(Fc fusion)
E21-M79	EnoGene	10ug	EUR 411.6

Antibodies didn’t have an effect on the motor efficiency or anxiousness scores in mice. These findings counsel that neuronal antibodies concentrating on completely different epitopes throughout the NMDA receptor could end in the same seizure phenotype.